FI83220C - Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3-dimetyl-1h-purin-2,6-dionderivat. - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3-dimetyl-1h-purin-2,6-dionderivat. Download PDFInfo
- Publication number
- FI83220C FI83220C FI853763A FI853763A FI83220C FI 83220 C FI83220 C FI 83220C FI 853763 A FI853763 A FI 853763A FI 853763 A FI853763 A FI 853763A FI 83220 C FI83220 C FI 83220C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- purine
- dimethyl
- compound
- acid addition
- Prior art date
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 239000002253 acid Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 9
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 239000011630 iodine Chemical group 0.000 claims description 2
- 229910052740 iodine Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- FAIAJSOSTNJZCI-UHFFFAOYSA-N purine-2,6-dione Chemical compound O=C1NC(=O)C2=NC=NC2=N1 FAIAJSOSTNJZCI-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 230000001624 sedative effect Effects 0.000 abstract description 4
- 230000002180 anti-stress Effects 0.000 abstract description 3
- 239000002249 anxiolytic agent Substances 0.000 abstract description 3
- 230000000949 anxiolytic effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000002539 anti-aggressive effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- -1 sulfonyloxy group Chemical group 0.000 description 16
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229960004046 apomorphine Drugs 0.000 description 7
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 6
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical class C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 4
- OJOSYHJYEWUYGU-UHFFFAOYSA-N 7-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 OJOSYHJYEWUYGU-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QCIARNIKNKKHFH-UHFFFAOYSA-N 7-(2-chloroethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCCl)C=N2 QCIARNIKNKKHFH-UHFFFAOYSA-N 0.000 description 2
- ZDYHRRFHPRZGRR-UHFFFAOYSA-N 7-(3-chloropropyl)-1,3-dimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.O=C1N(C)C(=O)N(C)C2=C1N(CCCCl)C=N2 ZDYHRRFHPRZGRR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- VXBSOZZOMUCYCM-WLHGVMLRSA-N (E)-but-2-enedioic acid 1,3-dimethyl-7-[3-[4-(7-methyl-1H-indol-3-yl)piperidin-1-yl]propyl]purine-2,6-dione Chemical compound OC(=O)\C=C\C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCN(CC1)CCC1C1=CNC2=C1C=CC=C2C VXBSOZZOMUCYCM-WLHGVMLRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- ALNXBNRDOANKRI-UHFFFAOYSA-N 3-(3,6-dihydro-2h-pyridin-1-yl)-1h-indole Chemical compound C1C=CCCN1C1=CNC2=CC=CC=C12 ALNXBNRDOANKRI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XOYQYCDKGORDBS-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indol-5-ol Chemical compound C12=CC(O)=CC=C2NC=C1C1CCNCC1 XOYQYCDKGORDBS-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- IEMKEYGFKOGIGY-UHFFFAOYSA-N 7-[2-[4-(1H-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 IEMKEYGFKOGIGY-UHFFFAOYSA-N 0.000 description 1
- ZLNPNFODBYKLSJ-UHFFFAOYSA-N 7-[2-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(Cl)C=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 ZLNPNFODBYKLSJ-UHFFFAOYSA-N 0.000 description 1
- PDFWVEXNHSBEAZ-UHFFFAOYSA-N 7-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(F)C=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 PDFWVEXNHSBEAZ-UHFFFAOYSA-N 0.000 description 1
- CUGUVZADROLXGZ-UHFFFAOYSA-N 7-[2-[4-(5-hydroxy-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(O)C=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 CUGUVZADROLXGZ-UHFFFAOYSA-N 0.000 description 1
- FVOFQAFSCCMCHU-UHFFFAOYSA-N 7-[2-[4-(5-methoxy-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(CC1)CCC1C1=CNC2=CC=C(OC)C=C21 FVOFQAFSCCMCHU-UHFFFAOYSA-N 0.000 description 1
- JXVMDPLIKYQEAB-UHFFFAOYSA-N 7-[2-[4-(6-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound FC1=CC=C2C(C=3CCN(CC=3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 JXVMDPLIKYQEAB-UHFFFAOYSA-N 0.000 description 1
- OCIGEVWGDSVNTO-UHFFFAOYSA-N 7-[3-[4-(1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C=3CCN(CC=3)CCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 OCIGEVWGDSVNTO-UHFFFAOYSA-N 0.000 description 1
- ATEJNXQFFUAUTB-UHFFFAOYSA-N 7-[3-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(Cl)C=C2C(C3CCN(CC3)CCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 ATEJNXQFFUAUTB-UHFFFAOYSA-N 0.000 description 1
- WNGLJOPEYUIVEM-UHFFFAOYSA-N 7-[3-[4-(5-methoxy-1h-indol-3-yl)piperidin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCN(CC1)CCC1C1=CNC2=CC=C(OC)C=C21 WNGLJOPEYUIVEM-UHFFFAOYSA-N 0.000 description 1
- KYEVGHAGJZAHEB-UHFFFAOYSA-N 7-[4-[4-(1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]butyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C=3CCN(CC=3)CCCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 KYEVGHAGJZAHEB-UHFFFAOYSA-N 0.000 description 1
- AICBGCXGNYXKLH-UHFFFAOYSA-N 7-[4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(F)C=C2C(C3CCN(CC3)CCCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 AICBGCXGNYXKLH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- AGWJMIKCFYNRMU-UHFFFAOYSA-N CC1=C2C(=CC=C1)C(=CN2)C3CCN(CC3)CCN4CN=C5C4=CN(CN5C)C Chemical compound CC1=C2C(=CC=C1)C(=CN2)C3CCN(CC3)CCN4CN=C5C4=CN(CN5C)C AGWJMIKCFYNRMU-UHFFFAOYSA-N 0.000 description 1
- BKLDLUFZXHBNSS-UHFFFAOYSA-N CCC([CH2-])O Chemical compound CCC([CH2-])O BKLDLUFZXHBNSS-UHFFFAOYSA-N 0.000 description 1
- QDGCKJOYUITKLB-UHFFFAOYSA-N CN1CN(C2=NCN(C2=C1)CCCN3CCC(CC3)C4=CNC5=C4C=CC(=C5)F)C Chemical compound CN1CN(C2=NCN(C2=C1)CCCN3CCC(CC3)C4=CNC5=C4C=CC(=C5)F)C QDGCKJOYUITKLB-UHFFFAOYSA-N 0.000 description 1
- AJIOMORFVHVUAV-UHFFFAOYSA-N CN1CN(C2=NCN(C2=C1)CCN3CCC(CC3)C4=CNC5=CC=CC=C54)C Chemical compound CN1CN(C2=NCN(C2=C1)CCN3CCC(CC3)C4=CNC5=CC=CC=C54)C AJIOMORFVHVUAV-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- VPJXWABCVUWOPD-UHFFFAOYSA-N OC([CH2-])C(C)O Chemical compound OC([CH2-])C(C)O VPJXWABCVUWOPD-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VLSTXUUYLIALPB-UHFFFAOYSA-N n-propan-2-ylpropan-1-amine Chemical compound CCCNC(C)C VLSTXUUYLIALPB-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65656184 | 1984-10-01 | ||
| US06/656,561 US4548939A (en) | 1984-10-01 | 1984-10-01 | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI853763A0 FI853763A0 (fi) | 1985-09-30 |
| FI853763L FI853763L (fi) | 1986-04-02 |
| FI83220B FI83220B (fi) | 1991-02-28 |
| FI83220C true FI83220C (fi) | 1991-06-10 |
Family
ID=24633577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI853763A FI83220C (fi) | 1984-10-01 | 1985-09-30 | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3-dimetyl-1h-purin-2,6-dionderivat. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4548939A (enExample) |
| EP (1) | EP0177087B1 (enExample) |
| JP (1) | JPH0653742B2 (enExample) |
| CN (1) | CN1011311B (enExample) |
| AT (1) | ATE60604T1 (enExample) |
| AU (1) | AU576386B2 (enExample) |
| CA (1) | CA1262348A (enExample) |
| DE (1) | DE3581577D1 (enExample) |
| DK (1) | DK163996C (enExample) |
| ES (1) | ES8609324A1 (enExample) |
| FI (1) | FI83220C (enExample) |
| GR (1) | GR852375B (enExample) |
| IE (1) | IE58747B1 (enExample) |
| NO (1) | NO162069C (enExample) |
| NZ (1) | NZ213498A (enExample) |
| PT (1) | PT81229B (enExample) |
| ZA (1) | ZA857553B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH648559A5 (de) * | 1981-07-20 | 1985-03-29 | Siegfried Ag | Theophyllinderivate und verfahren zu deren herstellung. |
| US4742057A (en) * | 1985-12-05 | 1988-05-03 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic thiazole compounds |
| AU611469B2 (en) * | 1987-08-13 | 1991-06-13 | Glaxo Group Limited | Indole derivatives |
| GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| DK733788A (da) * | 1988-01-14 | 1989-07-15 | Fujisawa Pharmaceutical Co | Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf |
| GB8819024D0 (en) * | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| DK292A (da) * | 1991-11-29 | 1992-01-02 | Tanisake Kk | Middel |
| DE4414113A1 (de) * | 1994-04-22 | 1995-10-26 | Merck Patent Gmbh | 3-Indolylpiperidine |
| ES2609912T3 (es) * | 2007-06-22 | 2017-04-25 | Hydra Biosciences, Inc. | Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 |
| WO2010039289A2 (en) | 2008-05-14 | 2010-04-08 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
| WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2322470A1 (de) * | 1973-05-04 | 1974-11-21 | Boehringer Sohn Ingelheim | Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung |
| FR2334358A1 (fr) * | 1975-12-12 | 1977-07-08 | Sogeras | Nouveaux medicaments derives de l'indole |
| FR2362628A1 (fr) * | 1976-08-26 | 1978-03-24 | Roussel Uclaf | Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments |
| EP0011399A1 (en) * | 1978-11-11 | 1980-05-28 | FISONS plc | N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them |
| DE2922159A1 (de) * | 1979-05-31 | 1980-12-04 | Boehringer Mannheim Gmbh | Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US4426383A (en) * | 1980-09-04 | 1984-01-17 | Eisai Co., Ltd. | Theophylline and theobromine derivatives |
| US4359468A (en) * | 1981-02-25 | 1982-11-16 | Boehringer Ingelheim Ltd. | Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones |
| US4443451A (en) * | 1981-07-15 | 1984-04-17 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidin-5-one derivatives |
| CH648559A5 (de) * | 1981-07-20 | 1985-03-29 | Siegfried Ag | Theophyllinderivate und verfahren zu deren herstellung. |
-
1984
- 1984-10-01 US US06/656,561 patent/US4548939A/en not_active Expired - Fee Related
-
1985
- 1985-07-30 CN CN85105804A patent/CN1011311B/zh not_active Expired
- 1985-09-10 CA CA000490317A patent/CA1262348A/en not_active Expired
- 1985-09-16 NZ NZ213498A patent/NZ213498A/en unknown
- 1985-09-18 AT AT85201484T patent/ATE60604T1/de not_active IP Right Cessation
- 1985-09-18 EP EP85201484A patent/EP0177087B1/en not_active Expired - Lifetime
- 1985-09-18 DE DE8585201484T patent/DE3581577D1/de not_active Expired - Fee Related
- 1985-09-27 JP JP60212731A patent/JPH0653742B2/ja not_active Expired - Lifetime
- 1985-09-30 AU AU48124/85A patent/AU576386B2/en not_active Ceased
- 1985-09-30 ES ES547447A patent/ES8609324A1/es not_active Expired
- 1985-09-30 IE IE240385A patent/IE58747B1/en not_active IP Right Cessation
- 1985-09-30 DK DK444085A patent/DK163996C/da not_active IP Right Cessation
- 1985-09-30 NO NO853856A patent/NO162069C/no unknown
- 1985-09-30 GR GR852375A patent/GR852375B/el unknown
- 1985-09-30 FI FI853763A patent/FI83220C/fi not_active IP Right Cessation
- 1985-09-30 ZA ZA857553A patent/ZA857553B/xx unknown
- 1985-10-01 PT PT81229A patent/PT81229B/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI853763A0 (fi) | 1985-09-30 |
| PT81229B (pt) | 1987-11-30 |
| GR852375B (enExample) | 1986-01-31 |
| EP0177087B1 (en) | 1991-01-30 |
| DK444085D0 (da) | 1985-09-30 |
| DK444085A (da) | 1986-04-02 |
| IE852403L (en) | 1986-04-01 |
| JPH0653742B2 (ja) | 1994-07-20 |
| ZA857553B (en) | 1987-05-27 |
| ATE60604T1 (de) | 1991-02-15 |
| NO853856L (no) | 1986-04-02 |
| PT81229A (en) | 1985-11-01 |
| DK163996B (da) | 1992-04-27 |
| FI853763L (fi) | 1986-04-02 |
| CN85105804A (zh) | 1986-10-22 |
| EP0177087A2 (en) | 1986-04-09 |
| NO162069C (no) | 1989-11-01 |
| DK163996C (da) | 1992-09-21 |
| DE3581577D1 (de) | 1991-03-07 |
| EP0177087A3 (en) | 1986-06-11 |
| FI83220B (fi) | 1991-02-28 |
| NO162069B (no) | 1989-07-24 |
| JPS6187681A (ja) | 1986-05-06 |
| AU4812485A (en) | 1986-04-10 |
| IE58747B1 (en) | 1993-11-03 |
| US4548939A (en) | 1985-10-22 |
| AU576386B2 (en) | 1988-08-25 |
| ES547447A0 (es) | 1986-07-16 |
| ES8609324A1 (es) | 1986-07-16 |
| CA1262348A (en) | 1989-10-17 |
| CN1011311B (zh) | 1991-01-23 |
| NZ213498A (en) | 1988-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5792768A (en) | Antipsychotic benzimidazole derivatives | |
| EP0464558B1 (en) | Antimigraine alkoxypyrimidine derivatives | |
| EP0303507B1 (en) | Indole derivatives | |
| AU671836B2 (en) | Fused imidazole and triazole derivatives as 5-HT1 receptor agonists | |
| US4820710A (en) | Benzimidazole derivatives and pharmaceutical compositions containing them | |
| CS227690B2 (en) | Manufacture of derivatives of 5h-thiazolo-and 5h-1,3,4-thiadiazolo/3,2-a/pirimidin-5-pyrimidin-5-on and 3,4-dihydro-2h,6h-pyrimido/2,1-b/ /1,3/-thiazin-6-on | |
| PT98168B (pt) | Processo para a preparacao de novos derivados do indole e de composicoes farmaceuticas que os contem | |
| FI83220C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3-dimetyl-1h-purin-2,6-dionderivat. | |
| CS256366B2 (en) | Method of new 3-(1-piperidinylalkyl)-4h-pyridol(1,2-pyrimidine-4-on derivatives production | |
| US5053411A (en) | N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds | |
| US5576336A (en) | Indole derivatives as dopamine D4 antagonists | |
| HUT74096A (en) | 3-indolylpiperidine derivatives | |
| JPH072839A (ja) | 縮合５員複素環化合物、それらの調製方法及びこれらの化合物を含む医薬組成物 | |
| EP0070562A1 (en) | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| AU3789901A (en) | Antipsychotic heterocycle compounds | |
| RU2047614C1 (ru) | Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты | |
| CS248020B2 (en) | Production method of the (+)-enantiomere or (+-)-racemical 4a,9b-trans-hexahydro-1h-pyridoindole derivatives | |
| EP0719264B1 (en) | Imidazolone and oxazolone derivatives as dopamine antagonists | |
| US5641787A (en) | Indole derivatives as dopamine D4 antagonists | |
| CZ148091A3 (en) | 3-(1-thiazolidinylbutyl-4-piperazinyl)-1h-indazoles, process of their preparation and their use as medicaments | |
| JPH07165754A (ja) | ヘテロアリールピペリジン、その製造方法およびそれを含有する医薬組成物 | |
| WO2006112828A1 (en) | Azaindole derivatives as inhibitors of p38 kinase | |
| JPH0733744A (ja) | インダゾール誘導体およびその塩 | |
| FI81800C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-bensisoxazol-3-yl-1-piperidinylalkylpyridopyrimidinon- och -tiazolopyrimidinonderivat. | |
| JPH0827149A (ja) | ピリミジノン誘導体およびその塩 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: JANSSEN PHARMACEUTICA N.V. |